Fabian Ido Didi, Sachs Dan, Moisseiev Joseph, Alhalel Amir, Grinbaum Aharon, Seligsohn Uri, Salomon Ophira
The Goldschleger Eye Institute, Tel Aviv University, Tel Aviv, Israel.
Am J Ophthalmol. 2009 Dec;148(6):920-4.e1. doi: 10.1016/j.ajo.2009.07.013. Epub 2009 Sep 5.
To assess the risks of intraoperative and postoperative bleeding associated with cataract extraction without prophylactic treatment in patients with severe factor XI (FXI) deficiency.
Prospective interventional case series.
Single institute.
Consecutive unrelated patients with severe FXI deficiency who underwent cataract extraction under topical anesthesia, with a clear corneal incision, phacoemulsification, and implantation of a foldable posterior chamber intraocular lens (PCIOL) were enrolled. Patients with associated intraocular conditions that could complicate the surgery were excluded.
Cataract extraction without prophylactic treatment for the FXI deficiency.
Assessment of intraoperative and postoperative ocular bleeding and other related complications.
Seven patients ranging in age from 61 to 95 years (median, 79) underwent phacoemulsification and PCIOL implantation in 11 eyes. Five patients (71%) were homozygotes for type II mutation of the FXI gene (activity level of <1 U/dl), 1 patient was a homozygote for type III mutation (activity level of 11 U/dl), and 1 patient was a compound heterozygote for types II and III (activity level of 3 U/dl). Three of the patients (43%), all type II homozygotes, also had an inhibitor antibody to FXI. All 7 patients were followed for at least 1 week after the operation. The surgery was uneventful in all eyes, and neither major nor minor bleeding events were observed in any of the operated eyes during surgery and follow-up.
Cataract extraction by phacoemulsification in uncomplicated eyes can be performed safely without prophylactic treatment in patients with severe FXI deficiency with or without inhibitor antibodies against FXI.
评估重度凝血因子 XI(FXI)缺乏患者在未进行预防性治疗的情况下进行白内障摘除术时术中及术后出血的风险。
前瞻性干预性病例系列研究。
单一机构。
纳入连续的、无亲属关系的重度 FXI 缺乏患者,这些患者在表面麻醉下接受白内障摘除术,采用透明角膜切口、超声乳化术,并植入可折叠后房型人工晶状体(PCIOL)。排除伴有可能使手术复杂化的眼内疾病的患者。
对 FXI 缺乏未进行预防性治疗的白内障摘除术。
评估术中及术后眼部出血及其他相关并发症。
7 例年龄在 61 至 95 岁(中位数为 79)的患者的 11 只眼睛接受了超声乳化术和 PCIOL 植入术。5 例患者(71%)为 FXI 基因 II 型突变纯合子(活性水平<1 U/dl),1 例患者为 III 型突变纯合子(活性水平为 11 U/dl),1 例患者为 II 型和 III 型复合杂合子(活性水平为 3 U/dl)。3 例患者(43%),均为 II 型纯合子,还存在 FXI 抑制性抗体。所有 7 例患者术后均至少随访 1 周。所有眼睛手术均顺利,在手术及随访期间,任何一只手术眼均未观察到重大或轻微出血事件。
对于伴有或不伴有 FXI 抑制性抗体的重度 FXI 缺乏患者,在无并发症的眼中进行超声乳化白内障摘除术时,无需预防性治疗即可安全进行。